Lisinostad

Quick links to important sections

Lisinostad

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lisinostad

Quick Facts

Property Description
Active ingredient Lisinopril
Form Oral Tablet
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
Common use Cardiovascular support and blood pressure management
Origin Synthetic peptide derivative

What Type of Medicine is Lisinostad?

Lisinostad is a prescription-only medication that belongs to the class of Angiotensin-Converting Enzyme (ACE) Inhibitors, a category clinically recognized for its role as a mainstay in treating hypertension. It is classified as an Antihypertensive Agent, confirming its fundamental purpose in helping to manage pressure within the circulatory system to support cardiovascular health. The primary active ingredient is Lisinopril, which is a synthetic peptide derivative and lysine-analog. This preparation is generally used as a foundational step in establishing long-term pressure control.


Lisinopril and Calcium Hydrogen Phosphate: Composition and Differentiation

The composition of Lisinostad is centered on the single therapeutic compound Lisinopril, which is chemically distinct from ACE Inhibitor prodrugs. Lisinopril is intrinsically active and acts directly after ingestion, providing a consistent, long-acting mechanism. In the oral tablet formulation, the excipient Calcium Hydrogen Phosphate (Dibasic Calcium Phosphate) is used as a filler and binder. This structural choice ensures the precise dosage of Lisinopril is reliably delivered, a crucial pharmaceutical feature differentiating the quality and integrity of various preparations.


What is the General Purpose of ACE Inhibitors?

The general purpose of this medication is to facilitate vasorelaxation and consequentially help reduce strain on the circulatory system. Lisinostad achieves this by inhibiting the Angiotensin-Converting Enzyme, which prevents the formation of the potent natural chemical Angiotensin II that causes blood vessels to tighten and constrict. This action confirms that the medication supports the heart and arteries by generally lowering systemic vasopressor activity through the targeted disruption of the Renin-Angiotensin-Aldosterone System (RAAS), offering a mechanism often preferred in initial therapy.

What side effects are possible with Lisinostad?

Possible Side Effects and Safety Information

The official safety profile for Lisinostad (Lisinopril) classifies adverse reactions based on their reported frequency and the specific body systems affected, according to regulatory standards (e.g., FDA, EMA). This information is descriptive and not intended as clinical advice.


Documented Adverse Reactions and Frequencies

Adverse reactions are formally grouped into categories. Common effects, reported in up to 1 in 10 users, typically include headache, dizziness, diarrhoea, and a persistent, non-productive cough. Uncommon effects may involve fatigue, rash, or changes in taste perception. Rare and Very Rare effects, such as pancreatitis or severe skin reactions, are also documented in the official labeling.


Serious Adverse Reactions and Safety Constraints

Certain reactions, though infrequent, are clinically significant and are highlighted in regulatory documents. The most serious risk associated with this class of medicine is angioedema (rapid swelling of the face, throat, or tongue), which has the potential for airway obstruction. Other serious reactions include hepatic failure (severe liver injury) and acute renal failure.

Safety Restrictions: The medicine is contraindicated in individuals with a history of angioedema related to prior ACE inhibitor therapy. Furthermore, it is restricted for use during the second and third trimesters of pregnancy due to the documented risk of foetal injury, underscoring its population-specific safety constraints. The risk of hypotension (low blood pressure) is often noted as being more likely following the initial dose or during dose escalation.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Lisinostad is documented to result primarily in Hypotension (excessively low blood pressure), which is the most likely clinical manifestation based on regulatory information. Associated signs may include fainting (syncope), dizziness, and lightheadedness due to systemic compromise. In severe cases, documented outcomes include Acute Renal Failure and Hyperkalemia (elevated potassium levels), which affect the renal and metabolic systems.

Mandatory Emergency Actions

Domain Regulatory Requirement
Help-Seeking Seek immediate medical attention for any symptomatic overdose or large ingestion. Call emergency services or Poison Control if severe symptoms like collapse or seizure occur.
Antidote Status No specific antidote is known. Management is symptomatic and supportive to maintain critical organ function.
Monitoring Hospital monitoring is required for symptomatic or hypotensive patients. Patients who are asymptomatic must be observed for a minimum of four to six hours to monitor for delayed effects.

Intravenous (IV) fluids are the officially described initial supportive measure to correct hypotension. Population-specific notes indicate that patients with pre-existing renal disease may be at an increased risk of developing acute kidney injury when experiencing significant low blood pressure.

Therapeutic Uses of Lisinostad

What Lisinostad Treats: Main Uses and Benefits

Lisinostad is generally used in therapeutic domains related to cardiovascular health. It is applied in contexts involving heightened systemic burden and where supportive symptom management is appropriate for managing sustained systemic pressure and heart function. The medication is commonly used to help with high blood pressure, managing heart failure, and is considered relevant after a heart attack.

The medication is relevant for easing symptoms related to systemic imbalance that may appear due to persistently high vascular pressure, as well as managing symptoms that interfere with daily comfort, such as those caused by cardiac strain and fluid retention. This application is crucial during phases when symptoms become more noticeable or in clinical settings that involve acute or unstable symptom patterns following a major cardiac event.

“This supportive role helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.”

Lisinostad contributes to easing the overall symptom load for patients and is relevant for easing the long-term risk of major cardiovascular complications. It also may assist with maintaining functional stability of the kidneys in high-risk patients, which supports general well-being during symptomatic phases.


Quick Fact: Relief for Vascular Strain

Lisinostad supports the long-term management of symptoms associated with pressure on blood vessels, providing support that helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Lisinostad (Lisinopril) is an Angiotensin-Converting Enzyme (ACE) inhibitor whose eligibility is defined by absolute prohibitions and specific patient restrictions according to official regulatory labeling.

Contraindicated Populations (Must Not Use)

Contraindication Condition or Context
History of Angioedema Related to previous ACE inhibitor use, or due to hereditary/idiopathic causes.
Pregnancy Contraindicated in the second and third trimesters due to fetal injury risk; must be discontinued immediately upon detection.
Drug Combinations Concomitant use with a Neprilysin Inhibitor (e.g., sacubitril) or within 36 hours of switching.
Diabetes/Renal Impairment Concomitant use with Aliskiren in patients with diabetes or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2).

Eligibility and Restrictions

Age-Related Eligibility

  • Adults: Eligible for all approved uses.
  • Pediatric Use: Approved only for hypertension in children 6 years of age and older. Use is not recommended for children younger than 6 years of age.
  • Kidney Function: Safety and effectiveness are not established for pediatric patients with poor kidney function (GFR < 30 mL/min/1.73 m^2).

Conditional Use

  • Use requires caution in patients who are volume-depleted, have severe renal impairment (Creatinine Clearance < 30 mL/min), or have specific heart valve conditions like aortic stenosis. Use is not recommended if a patient is hemodynamically unstable after a heart attack.

What should I know about interactions with other medicines?

Lisinopril Interactions with other medicines and products

Lisinopril, an Angiotensin-Converting Enzyme (ACE) inhibitor, may interact with several other medicines and products, necessitating careful monitoring. Certain combinations are contraindicated due to the risk of serious adverse effects.

Interacting Product Category Potential Effect/Restriction
Neprilysin Inhibitors (e.g., sacubitril/valsartan) Contraindicated. Increased risk of angioedema (severe swelling). Lisinopril must not be started within 36 hours of stopping a Neprilysin Inhibitor, and vice versa.
Aliskiren Contraindicated in patients with diabetes or moderate-to-severe kidney impairment (GFR < 60 mL/min). Increases the risk of hypotension, hyperkalemia, and kidney problems.
Potassium-Sparing Diuretics (e.g., spironolactone), Potassium Supplements, Salt Substitutes containing potassium Increased risk of hyperkalemia (high blood potassium levels), which can affect heart rhythm. Co-administration requires frequent monitoring of serum potassium.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May reduce the blood pressure-lowering effect of Lisinopril. Can also increase the risk of worsening kidney function, especially in elderly or volume-depleted individuals.
mTOR Inhibitors (e.g., sirolimus, everolimus) Increased risk of angioedema (swelling).
Lithium Lisinopril may reduce the clearance of lithium, leading to increased lithium blood levels and potential toxicity. Monitor serum lithium levels closely.
Antidiabetic Agents (e.g., insulin, oral hypoglycemic agents) Increased risk of hypoglycemia (low blood sugar), particularly at the start of ACE inhibitor therapy.

Co-administration with other diuretics may result in excessive hypotension (low blood pressure), often requiring a dose adjustment of the diuretic before starting Lisinopril.

Mechanism of Action

Lisinostad acts as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE), which is primarily a peptidyl dipeptidase located on the surface of vascular endothelial cells and in tissues like the kidney.

This interaction prevents the catalytic conversion of Angiotensin I into the potent vasoconstrictor, Angiotensin II, thereby interrupting the Renin-Angiotensin-Aldosterone System (RAAS) cascade. The subsequent reduction in circulating and tissue Angiotensin II concentration leads to a decrease in vasopressor activity and a reduced stimulus for the adrenal cortex to release Aldosterone.

Downstream consequences include a net reduction in systemic vascular resistance due to arteriolar relaxation (vasodilation) and an increase in the excretion of sodium and water by the renal tubules, which is mediated by the decreased Aldosterone levels. This systemic modulation results in a reduction in overall intravascular volume and a modification of arterial wall tension.

Dosage and Administration Information

Lisinostad is administered through the oral route as either a tablet or a liquid solution, which dictates the primary method of use. The usage pattern for adults is based on a strict once-daily schedule, and the medication may be taken independently of food.

The initial dosage is determined by the specific condition being addressed. For standard hypertension management, therapy typically begins at 10 mg once daily. In contrast, administration for heart failure generally commences with a lower initial dose, usually 2.5 mg or 5 mg. Following an acute heart attack, a specific, short-term dosage sequence involving escalating doses is followed over the initial 48 hours.

Use of Lisinostad is structured around a titration protocol, meaning the dose is adjusted by a healthcare professional at intervals of one to four weeks until the appropriate amount is achieved. While many conditions necessitate a long-term administration pattern, the post-heart attack regimen is designated to continue for at least six weeks.

Population-Specific Usage Adjustments

Population Dosing Rule (Label-Based)
Renal Impairment The starting dose must be halved for patients with significant kidney function limitations.
Pediatric (Age ge 6 years) Dosing for hypertension is initiated with a weight-based dose of up to 5 mg, not to exceed 40 mg daily.
Missed Dose If administration is missed, the dose should not be doubled; the patient is directed to resume the usual scheduled administration time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lisinostad


Evidence for Use in High Blood Pressure (Hypertension)

Research for Lisinostad's application in high blood pressure management included large-scale Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Studies focused on monitoring recorded reductions in systolic and diastolic blood pressure (BP) measurements and tracking major cardiovascular events, such as stroke or heart attack. Findings describe patterns where blood pressure level recordings showed patterns across observed patient groups. The available research was evaluated at a high level. However, some evidence suggests that outcomes related to stroke frequency may show mixed findings when examined against specific other therapies.


Evidence for Use in Heart Failure

The research base relies on landmark, long-term, controlled clinical trials that often extended follow-up for several years. These studies primarily included adults with symptomatic heart failure and reduced ejection fraction. Researchers monitored key outcomes related to all-cause and cardiovascular mortality, hospitalization frequency, and functional metrics. Findings describe patterns related to the frequency of mortality and re-hospitalization over the long observation periods. Research also explored whether observed patterns related to mortality was associated with the range of administered levels studied in the clinical trials.


Evidence for Use After a Heart Attack (Acute Myocardial Infarction)

Evidence for Lisinostad's evaluation following a heart attack was derived from large, multicenter, Randomized Open Trials. This research focused on a specific population: hemodynamically stable adults for whom observation began within a short timeframe (e.g., 24 hours) after the acute event. Trials described patterns related to survival rates over the initial six months of follow-up. The findings reflect the specific conditions under which they were conducted, and research provides limited insight into outcomes for patients who did not meet the stability criteria.


What Remains Uncertain About Lisinostad Research

Evidence is limited in several areas, reflecting ongoing research and specific trial design constraints. For example, some large comparative studies have reported mixed findings regarding the frequency of specific events like stroke when compared to some other categories of medication. The duration of observation needed to characterize long-term outcomes is not always fully established across all studied conditions, and data for certain demographic groups remain insufficient for broad conclusions.

Frequently Asked Questions (FAQ)

Common questions about Lisinostad (FAQ)


Q: How quickly does Lisinostad start working?

A: According to official product information, the onset of action for Lisinostad is typically observed within one hour after taking a single dose. The peak reduction in blood pressure is generally seen around six hours after administration. This sustained effect is consistent with how the medicine is typically administered once daily.


Q: Is Lisinostad the same type of drug as lisinopril or losartan?

A: The active ingredient in Lisinostad is Lisinopril, which is classified as an ACE (Angiotensin-Converting Enzyme) inhibitor. However, Losartan belongs to a completely different class of medicine called an ARB (Angiotensin II Receptor Blocker). While both classes target the same body system to manage blood pressure, they achieve their effect through distinct mechanisms, as described in regulatory documents.


Q: Is it okay to drink alcohol while using Lisinostad?

A: Regulatory documents state that alcohol may have additive effects with Lisinostad in lowering blood pressure. This combination can increase the risk of feeling dizzy, lightheaded, or even fainting. Official labeling indicates that discussions about alcohol use should take place with a healthcare provider.


Q: What happens if I stop taking Lisinostad suddenly?

A: Official guidance indicates that in patients using Lisinostad primarily for high blood pressure, abruptly stopping the medication has not typically been associated with a rapid or uncontrolled rise in blood pressure. Nonetheless, stopping treatment suddenly is generally not recommended. Any decision to discontinue or change treatment is typically a discussion for the patient and their prescribing healthcare professional.


Q: Can older adults or seniors take Lisinostad?

A: Yes, Lisinostad is used in the adult population. Official guidance indicates that dose adjustments are generally not based on age alone for older adults. However, official labeling does note that caution is advised, particularly when this medicine is taken alongside other drugs, such as certain pain relievers, especially in elderly or volume-depleted individuals.


Q: Does Lisinostad help protect the kidneys in people with diabetes?

A: Yes, the active ingredient in Lisinostad, Lisinopril, is formally indicated for managing certain kidney problems (known as diabetic nephropathy) that can occur in patients with diabetes. Official approvals specify that the medicine is indicated for managing certain kidney problems, which refers to the reduction of progression in this patient group.


Q: Is there a generic version of Lisinostad available?

A: Yes, the FDA has approved a generic version of the active ingredient, Lisinopril, in various strengths. Generic medicines contain the same active ingredient and are required to meet the same quality standards as the brand-name product.


Q: How long do the effects of Lisinostad last after taking a dose?

A: Studies and official product information show that the blood pressure-lowering effect of Lisinostad is maintained for at least 24 hours. This sustained effect is the pharmacological basis for why this medication is typically prescribed to be taken once a day.


Q: Do studies suggest Lisinostad is more effective in men or women?

A: Regulatory documents acknowledge that pharmacokinetic or pharmacodynamic differences between sexes may exist but do not generally conclude that Lisinopril is demonstrably more effective in one sex over the other based on major cardiovascular outcomes.


Q: Can Lisinostad be taken with vitamins or herbal products?

A: Official patient guidelines advise individuals not to start any new medicines, over-the-counter drugs, or herbal remedies without first informing their doctor or pharmacist. This guidance is provided as a standard precaution in the official patient materials.


Q: Is Lisinostad a controlled substance?

A: According to U.S. regulatory classifications (such as those from the DEA), the active ingredient in Lisinostad, Lisinopril, is not classified as a controlled substance. This means its distribution and use are regulated as a standard prescription medication.


Q: Is there evidence that Lisinostad can affect fertility?

A: Official information, such as that provided by the UK National Health Service (NHS), suggests that there is no clear evidence to indicate that taking Lisinopril reduces the ability to conceive (fertility) in either men or women.


Q: Does Lisinostad interact with common cold or flu medications?

A: Regulatory documents indicate that Lisinostad can interact with certain types of medicines found in cold and flu products, specifically Sympathomimetic agents (like decongestants). These agents can cause adverse cardiovascular effects or potentially elevate blood pressure. Official warnings state that patients are directed to inform their doctor before starting any new cold or flu medicines.


Q: What is the expected timeline to see the full benefit of Lisinostad?

A: While the initial effect of a single dose is quick, the process of achieving the full, optimal benefit of Lisinostad often requires time. Studies indicate that the greatest blood pressure reduction is often achieved after two to four weeks of therapy. This timeline for achieving optimal benefit is generally consistent with the period required for dose adjustment (titration).


Q: Are there any specific activities to limit while taking Lisinostad?

A: Yes, official warnings mention that because Lisinostad can cause side effects like dizziness, lightheadedness, or fainting, patients are advised to sit up or stand slowly. Official warnings describe that activities requiring full alertness, such as driving or operating heavy machinery, are generally not recommended until patients know how the medication affects them.


Q: Is Lisinostad known to cause heartburn or stomach upset?

A: Official documentation, while listing common side effects like diarrhea, also includes general gastrointestinal side effects and notes a possibility of upset stomach. This indicates that various forms of stomach or digestive discomfort may occur, though the specific term "heartburn" may not be explicitly listed.


Q: Can a person with asthma or breathing problems take Lisinostad?

A: Lisinostad is officially associated with a common side effect: a persistent, non-productive cough. More rarely, it can cause a serious reaction called angioedema, which involves swelling that can affect the airway. While these risks highlight the need for caution, official documents do not list pre-existing asthma as a contraindication.


Q: Do studies show a difference in outcomes based on when Lisinostad is taken (morning vs. evening)?

A: Official dosing guidance confirms that Lisinostad is a once-daily medicine and can generally be taken in the morning or evening. For most patients, the important factor is to take it at the same time every day, rather than the specific time of day.


Q: Does the medicine contain gluten or lactose?

A: The active ingredient is Lisinopril. Regulatory-cited information on excipients (inactive ingredients) confirms the use of Calcium Hydrogen Phosphate as a filler. Furthermore, stability data often indicates that lactose is typically avoided in many Lisinopril formulations due to chemical incompatibility, but patients should always check their specific prescription label for excipient information regarding allergens like gluten or lactose.


Q: What are the symptoms of using too much Lisinostad?

A: The most common and expected sign of using too much Lisinostad (overdosage) is severe hypotension (extremely low blood pressure), which could lead to symptoms like dizziness or fainting. A slow heart rate (bradycardia) may also occur, as described in the overdosage sections of official labeling.


Q: Is it safe to take Lisinostad while driving or operating heavy machinery?

A: Official product warnings state that because this medicine may affect your coordination, reaction time, or judgment (due to dizziness or fatigue), patients must be cautious. Official product warnings advise that driving or operating heavy machinery is not recommended until patients know how the medicine affects their body.

How should Lisinostad be stored and disposed of?

Storage and Disposal of Lisinopril

Lisinopril tablets must be stored at controlled room temperature, which is generally 20^circ to 25 C (68^circ to 77 F). The medication must be protected from moisture and excessive heat; it is officially mandated not to allow the tablets to freeze.

Container and Protection

The medicine should be kept in the original, dispensed container, ensuring it is tightly closed and light-resistant to maintain stability. For safety, it must be stored out of the sight and reach of children.

Disposal

Unused or expired Lisinopril must be disposed of in accordance with local requirements. Patients are instructed to consult a pharmacist or local waste disposal company for guidance on the proper method for discarding the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lisinostad found in:

A-Z Index: